Analyst Rating Update on Agenus (AGEN)

Agenus (NASDAQ:AGEN) : 5 analysts are covering Agenus (NASDAQ:AGEN) and their average rating on the stock is 1, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.

Agenus (NASDAQ:AGEN) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $14 and the lowest price target forecast is $6. The average forecast of all the analysts is $9.25 and the expected standard deviation is $3.59.

For the current week, the company shares have a recommendation consensus of Buy.

Agenus (NASDAQ:AGEN): stock turned positive on Tuesday. Though the stock opened at $3.7, the bulls momentum made the stock top out at $3.935 level for the day. The stock recorded a low of $3.7 and closed the trading day at $3.88, in the green by 6.89%. The total traded volume for the day was 895,602. The stock had closed at $3.63 in the previous days trading.

In an insider trading activity, Armen Garo H, CEO of Agenus Inc, executed a transaction worth $318,000 on May 6, 2016. A total of 100,000 shares were purchased at an average price of $3.18. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.